Human Health Division (HHD) Products
Product List by Therapeutic
Lactic Acid + Citric Acid + Potassium
Composition:
Feelfree Gel: Each gram gel contains Lactic Acid BP 18 mg, Citric Acid BP 10 mg & Potassium Bitartrate USP 4 mg.
Indication:
Feelfree is indicated for the prevention of pregnancy in female of reproductive potential for use as an on-demand method of contraception.
Dose & Administration:
Administer 5 g gel Feelfree vaginally by the applicator immediately before (or up to one hour before) each episode of vaginal intercourse. May use during any part of the menstrual cycle or as directed by the physicians.
Cefaclor
Composition:
Navacef™ 250 Capsule: Each capsule contains Cefaclor Monohydrate USP equivalent to 250 mg of Cefaclor.
Navacef™ 500 Capsule: Each capsule contains Cefaclor Monohydrate USP equivalent to 500 mg of Cefaclor.
Navacef™ PFS (100 ml): Each 5 ml contains Cefaclor Monohydrate USP equivalent to 125 mg of Cefaclor.
Navacef™ PFS (60 ml): Each 5 ml contains Cefaclor Monohydrate USP equivalent to 125 mg of Cefaclor.
Navacef™ Paediatric Drops (15 ml): Each 1.25 ml contains Cefaclor Monohydrate USP equivalent to 125 mg of Cefaclor
Indication
Respiratory Tract Infections: Pneumonia, bronchitis, pharyngitis, tonsillitis, otitis media.
Uninary Tract Infections: Pylonephritis, cystitis etc.
Skin & Soft Tissue Infections: Impetigo, pyodema, cellulitis, pruritis etc.
Dosage & Administration
Adults: 250 mg three times daily (Dose should be doubled in severe cases, max. 4 g daily). Children
over 1 month: 20 mg/kg/ day in three divided doses (Dose should be doubled in severe cases, max 1
g daily). 1-5 years: 125 mg three times daily, over 5 years: 250 mg three times daily, (Dose should be
doubled in severe cases), or as directed by the physician.
Cefuroxime
Composition
Fixcef 250 Tablet: Each film coated tablet contains Cefuroxime Axetil BP equivalent to Cefuroxime 250 mg.
Indication
Pharyngitis/tonsillitis, Acute bacterial otitis media, Acute bacterial maxillary sinusitis.
Acute bacterial exacerbations of chronic bronchitis and secondary bacterial infection of acute bronchitis,
Uncomplicated skin and skin-structure infections, Uncomplicated urinary tract infections,
Uncomplicated gonorrhoea (urethral and endocervical), Early lyme disease (erythema migrans).
Dosage & Administration
For oral administration
Fixcef™ Plus Tablet: The usual course of therapy with Cefuroxime-Clavulanic acid tablets is 5 to 7 days for treatment of
bronchitis and 7 to 10 days for other infections. Adolescents andAdults (13 years and older)
Pregabalin
Composition
Pregan™ 50: Each capsule contains Pregabalin INN 50 mg.
Pregan™ 75: Each capsule contains Pregabalin INN 75 mg
Indication
• Neuralgia: (a) pain from diabetic neuropathy, (b) postherpetic neuralgia
• Fibromyalgia
• Partial seizure / epilepsy: Pregabalin is also indicated as adjunctive therapy for adult
patients with partial onset seizures.
• Generalized anxiety disorder
Dose & Administration
Neuropathic pain: Adult 18 years: Initially 150 mg daily in 2-3 divided doses, dose can be increased if necessary after 3-7 days to 300 mg daily in 2-3 divided doses and it can be
increased further if necessary after 7 days to max. 600 mg daily in 2-3 divided doses.
Epilepsy: Adult over 18 years: Initially 25 mg twice daily, dose can be increased at 7 day intervals in steps of 50 mg daily to 300 mg daily in 2-3 divided doses and it can be increased further of necessary after 7 days to max. 600 mg daily in 2-3 divided doses.
Generalized anxiety disorder: Adult over 18 years: Initially 150 mg daily in 2-3 divided doses, dose can be increased if necessary at 7 day intervals in steps of 150 mg daily; max. 600 mg daily in 2-3 divided doses.
Fibromyalgia: The recommended dose of Pregabalin is 300-450 mg/day. Initial dose is 75 mg twice daily and may be increased to 150 mg twice daily within 1 week based on efficacy and tolerability. Patient who does not experience sufficient benefit with 300 mg/ day may be further
increased to 225 mg twice daily. Or as directed by the physician.
Pizotifen
COMPOSITION :
Pizofen™ Tablet : Each film coated tablet contains Pizotifen
malate BP equivalent to Pizotifen 0.5 mg
Pizofen™ TS Tablet : Each film coated tablet contains Pizotifen
malate BP equivalent to Pizotifen 1.5 mg
INDICATION :
It is used as prophylactic treatment of vascular headaches of the migraine types, such as classic migraine, common migraine and cluster headache.
DOSE AND ADMINISTRATION :
Adult : Usually 1.5 mg daily, which may be taken as a single
dose at night or in three divided doses. Dose should be adjusted to individual patient's requirements. Upto a maximum of 4.5 mg may be given as a single dose daily.
Children : Dose is 1 mg as a single dose at night using 0.5 mg
tablet. Maximum dose is upto 1.5 mg daily usually in divided
dose.
Or as directed by the physician.
Flunarizine
Composition
Imigra™ 5 Tablet: Each film coated tablet contains Flunarizine Dihydrochloride BP equivalent to 5 mg Flunarizine.
Imigra™ 10 Tablet: Each film coated tablet contains Flunarizine Dihydrochloride BP equivalent to 10 mg Flunarizine.
Imigra™ 5 Capsule: Each capsule contains Flunarizine Dihydrochloride BP equivalent to 5 mg Flunarizine.
Imigra™ 10 Capsule: Each capsule contains Flunarizine Dihydrochloride BP equivalent to 10 mg Flunarizine
Indication
O Symptomatic treatment of vestibular vertigo & dizziness.
O Peripheral vascular diseases (Intermittent claudication, Raynaud's phenomenon, paresthesia, cold extremities etc.).
O Epilepsy resistant to conventional anti-epileptic therapy.
O Prophylaxis of classic (with aura) or common (without aura) migraine.
Dose and Administration
For vertigo: The recommended maximum daily dose of Flunarizine in the treatment of vertigo is 10 mg daily in adults and 5 mg daily in children (<40 kg).
For epilepsy: An optimal therapeutic dosage in epileptic patients receiving other anti-epileptic drug is 15 mg to 20 mg daily in adults and 5 to 10 mg daily in children.
For migraine prophylaxis: Starting dose is 10 mg daily at night for adult patients less than 65 years of age and 5 mg daily for patients older than 65 years.
Maintenance treatment: If a patient's response is satisfactory and if a maintenance treatment is needed, the dose should be decreased. The patient should have 5 days treatment in a week at the same daily dose and 2 successive drug free days. Treatment should be stopped after 6 months and reinitiated only if the patient relapses.
Or as directed by the physician
Bisoprolol + Hydroclorothiazide
Composition:
Tabis™ Plus 2.5 Tablet: Each film coated tablet contains Bisoprolol Fumarate USP 2.5 mg and Hydrochlorothiazide BP 6.25 mg.
Tabis™ Plus 5 Tablet: Each film coated tablet contains Bisoprolol Fumarate USP 5 mg and Hydrochlorothiazide BP 6.25 mg.
Indication:
Tabis™ Plus is indicated for the management of hypertension.
Dose & Administration:
The initial dose is 2.5/6.25 mg once daily. Subsequent titration (14 day intervals) may be carried out with Tabis™ Plus tablets up to the maximum recommended dose
20/12.5 mg once daily as appropriate.
Bisoprolol
Composition
Tabis™ 2.5 Tablet: Each film coated tablet contains Bisoprolol Fumarate USP 2.5 mg.
Tabis™ 5 Tablet: Each film coated tablet contains Bisoprolol Fumarate USP 5 mg
Indications
• Hypertension
• Angina
• Adjunct in stable moderate to severe heart failure.
Dose & Administration
Hypertension: The dose of Bisoprolol must be individualized to the needs of the patient. The usual starting dose is 5 mg once daily. In some patients, 2.5 mg may be an appropriate starting dose. If the antihypertensive effect of 5 mg is inadequate, the dose may be increased to 10 mg and then, if
necessary, to 20 mg once daily.
Angina: Usually 10 mg once daily (5 mg may be adequate in some patients) max 20 mg daily.
Heart Failure: Initially 1.25 mg once daily (in the morning) for 1 week then, if well tolerated, increased to 2.5 mg once daily for 1 week, then 3.75 mg once daily for 1 week, then 5 mg once daily for 4 weeks, then 7.5 mg once daily for 4 weeks, then 10 mg once daily, max 10 mg daily.
Or as directed by the physician
Olmesartan + Hydrochlorothiazide
Composition:
Olmeben™ Plus 20/12.5 Tablet: Each film coated tablet contains Olmesartan Medoxomil USP 20 mg & Hydrochlorothiazide BP 12.5 mg
Indication:
It is indicated for the treatment of hypertension. This fixed dose combination is not indicated for initial therapy.
Dose & Administration:
Hypertension
The usual starting dose of Olmeben™ Plus 20/12.5 is one tablet once daily. Dosing should be
individualized. Depending on the blood pressure response, the dose may be titrated at intervals of
2-4 weeks.
Patients with Renal Impairment:
The usual regimens of therapy with Olmeben™ Plus 20/12.5 may be followed provided the patient's creatinine clearance is >30 mL/min. In patients with more severe renal impairment, loop diuretics are preferred to thiazides. So, Olmeben™ Plus 20/12.5 is not recommended. Patients with Hepatic Impairment: No dosage adjustment is necessary with hepatic impairment.
Or as directed by the physician.
Olmesartan
Composition:
Olmeben™ 20 Tablet: Each film coated tablet contains Olmesartan Medoxomil USP 20 mg.
Olmeben™ 40 Tablet: Each film coated tablet contains Olmesartan Medoxomil USP 40 mg.
Indication:
It is indicated for the treatment of hypertension. It may be used alone or in combination with other antihypertensive agents.
Dose & Administration:
The usual starting dose of Olmesartan is 20 mg once daily. Dosing should be individualized. Depending on the blood pressure response, the dose may be increased after 2 weeks to 40 mg. Olmesartan may be administered with or without food. No initial dosage adjustment is recommended for elderly patients, for patients with moderate to marked renal impairment (creatinine clearance < 40 ml/min) or with moderate to marked hepatic dysfunction. If blood pressure is not controlled by Olmesartan alone, a diuretic may be added. Olmsartan may be administerd with other antihypertensive agents. Or as directed by the physician.
Rosuvatatin
Composition
Nestor™ 5 Tablet: Each film coated tablet contains Rosuvastatin Calcium BP equivalent to Rosuvastatin 5 mg.
Nestor™ 10 Tablet: Each film coated tablet contains Rosuvastatin Calcium BP equivalent to Rosuvastatin 10 mg.
Indication
Heterozygous Hypercholesterolemia (Familial and Nonfamilial) Homozygous Hypercholesterolemia (Familial) Mixed Dyslipidemia (Fredrickson Type lla and lib)
Dosage & Administration
For asian people, initial starting dose of Rosuvastatin is 5 mg once daily. The dose range of Rosuvastatin is 5-40 mg once daily. Heterozygous Hypercholesterolemia (Familial and Nonfamilial) and Mixed Dyslipidemia (Fredrickson Type lla and lib) The usual recommended starting dose of rosuvastatin is 10 mg once daily. Initiation of therapy with 5 mg once daily may be considered for patients requiring less aggressive LDL-C reductions or who have predisposing factors for myopathy. For patients with marked hypercholesterolemia (LDLC > 190 mg/dL) and aggressive lipid targets, a 20-mg starting dose may be considered. The 40-mg dose of rosuvastatin should be reserved for those patients who have not achieved goal LDL-C at 20 mg. After initiation and/or upon titration of rosuvastatin, lipid levels should be analyzed within 2 to 4 weeks and dosage adjusted accordingly.
Homozygous Hypercholesterolemia (Familial):
The recommended starting dose of rosuvastatin is 20 mg once daily in patients with homozygous FH. The maximum recommended daily dose is 40 mg. Rosuvastatin should be used in these patients as an adjunct to other lipid-lowering treatments (e.g., LDL apheresis) or if such treatments are unavailable. Patients with renal insufficiency: No modification of dosage is necessary for patients with mild to moderate renal insufficiency. For patients with severe renal impairment (CLcr <30 mL/min/1.73 m2) not on hemodialysis, dosing of rosuvastatin should be started at 5 mg once daily and should not be exceeded 10 mg once daily or as directed by the physician.
Clopidogrel + Aspirin
Composition:
Navix™ Plus Tablet: Each film coated tablet contains Clopidogrel Bisulfate USP equivalent to Clopidogrel 75 mg and Aspirin BP 75 mg.
Indication:
The preparation is used for the prevention of ischemic events, myocardial infarction, stroke and cardiovascular death in patients with acute coronary syndrome.
Dosage & Administration:
The recommended dose is once daily or as directed by the physician.
Clopidogrel
Composition:
Navix™ Tablet: Each film coated tablet contains Clopidogrel Bisulfate USP equivalent to 75 mg Clopidogrel.
Indication:
Clopidogrel is indicated for the reduction of atherosclerotic events (myocardial infarction, stroke and vascular death) and in patient with atherosclerosis documented recent stroke, recent myocardial infarction or established peripheral arterial disease (PAD).
Dosage & Administration:
The recommended dose of Clopidogrel is 75 mg once daily with or without food. No dosage adjustment is required for elderly patients or patients with renal disease or as directed by the physician.
Levamlodipine
Composition
L-Amlo 1.25 Tablet:Each tablet contains Levamlodipine Maleate INN equivalent to
Levamlodipine 1.25 mg.
L-Amlo 2.5 Tablet:Each tablet contains Levamlodipine Maleate INN equivalent to
Levamlodipine 2.5 mg.
L-Amlo 5 Tablet:Each tablet contains Levamlodipine Maleate INN equivalent to Levamlodipine
5 mg.
Indication
L-Amlo is a calcium channel blocker which is used alone or in combination with other
antihypertensive agents for the treatment of hypertension. Lowering blood pressure reduces the
risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions.
Dose & Administration
Adult recommended dose: 2.5 mg orally once daily with maximum dose 5 mg once daily. For small, fragile or elderly patients or patients with hepatic insufficiency, 1.25 mg once daily starting dose is recommended.
Paediatric starting dose: 1.25 mg to 2.5 mg once daily or as directed by the physicians
